Cover Image
市場調查報告書

燒燙傷:開發中產品分析

Burns - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 213115
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
燒燙傷:開發中產品分析 Burns - Pipeline Review, H1 2018
出版日期: 2018年02月27日 內容資訊: 英文 97 Pages
簡介

所謂燒燙傷 (燙傷,燒傷) 是指由於熱能和化學藥品,電力,日光,放射性核能等造成人體組織的損傷。主要的症狀有疼痛 (燒燙傷程度愈大疼痛也愈強) ,及皮膚的發炎·腫包,水痘,炭化,變色 (變黑) 等。主要的治療方法有抗生素和止痛藥等。

本報告提供全球各國治療燒燙傷所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

燒燙傷概要

治療藥的開發

  • 燒燙傷開發中產品:概要
  • 燒燙傷開發中產品:比較分析

各企業開發中的的燒燙傷治療藥

大學/研究機關研究中的燒燙傷治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

燒燙傷治療藥:開發中的產品一覽 (各企業)

燒燙傷治療藥:研究中的產品一覽 (各大學/研究機關)

燒燙傷開發治療藥的企業

  • Adocia
  • AlgiPharma AS
  • Amarantus Bioscience Holdings, Inc.
  • American Gene Technologies International Inc.
  • Biogenomics Limited
  • CytoTools AG
  • Destiny Pharma Limited
  • Lakewood-Amedex Inc
  • Madam Therapeutics B.V.
  • MediWound Ltd.
  • Mitochon Pharmaceuticals, Inc.
  • Phosphagenics Limited
  • Se-cure Pharmaceuticals Ltd.
  • Sinclair Pharma Plc
  • Stratatech Corporation
  • Tissue Therapies Limited
  • USV Pvt Ltd

燒燙傷:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

燒燙傷治療藥:開發暫停的產品

燒燙傷治療藥:開發中止的產品

燒燙傷相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10205IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2018, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 2, 16, 5 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burns - Overview
    • Burns - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Burns - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Burns - Companies Involved in Therapeutics Development
    • AlgiPharma AS
    • Alliance Pharma Plc
    • Amarantus Bioscience Holdings Inc
    • American Gene Technologies International Inc
    • CFM Pharma Holding BV
    • CytoTools AG
    • Destiny Pharma Ltd
    • Energenesis Biomedical Co Ltd
    • Lakewood-Amedex Inc
    • Madam Therapeutics BV
    • MallInckrodt Plc
    • MediWound Ltd
    • NanoBio Corp
    • Phagelux Inc
    • Se-cure Pharmaceuticals Ltd
    • Therapure Biopharma Inc
    • USV Pvt Ltd
  • Burns - Drug Profiles
    • (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • albumin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AyuV-25 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BH-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bromelains - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Dermatology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENERGIF-711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epidermal growth factor biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMSP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neu-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NJ-01SS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligomer G for Burn Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEP-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SFR-9X0125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • silver sulfadiazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium hypochlorite - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SST-024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vanadis-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XF-70 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Burns - Dormant Projects
  • Burns - Discontinued Products
  • Burns - Product Development Milestones
    • Featured News & Press Releases
      • Jan 23, 2018: Amarantus Subsidiary Cutanogen Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
      • Jan 04, 2018: Amarantus Subsidiary Cutanogen Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
      • Oct 31, 2017: NeoMatrix Therapeutics Enters Clinical Stage as Investigational New Drug Application for NMT-cP12 Goes Into Effect
      • Sep 11, 2017: MediWound's NexoBrid Wins Best Poster Presentation Award at the 17th European Burns Association Congress
      • Sep 06, 2017: MediWounds NexoBrid Highlighted in 43 Presentations at the 17th European Burns Association Congress
      • Jul 19, 2017: BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid Indications
      • Jun 23, 2017: BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound's NexoBrid Development
      • Jun 16, 2017: Independent Study in Germany Shows NexoBrid Reduces Average Burn Treatment Costs by nearly 30% Versus Standard of Care
      • Jun 02, 2017: Poster Presentation Highlighting NexoBrid Awarded "Best Poster" at the 52nd Congress of the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery
      • Mar 30, 2017: MediWound's NexoBrid to be Highlighted in Multiple Presentations at the Symposium on Advanced Wound Care Spring
      • Mar 14, 2017: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 49th Annual Meeting
      • Mar 03, 2017: Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid in Burn Management Published in BioMed Research International
      • Feb 09, 2017: Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area
      • Feb 06, 2017: MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid Expanding Treatment of Severe Burns to Children Age One to Four
      • Aug 24, 2016: MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Burns, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Burns - Pipeline by AlgiPharma AS, H1 2018
  • Burns - Pipeline by Alliance Pharma Plc, H1 2018
  • Burns - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
  • Burns - Pipeline by American Gene Technologies International Inc, H1 2018
  • Burns - Pipeline by CFM Pharma Holding BV, H1 2018
  • Burns - Pipeline by CytoTools AG, H1 2018
  • Burns - Pipeline by Destiny Pharma Ltd, H1 2018
  • Burns - Pipeline by Energenesis Biomedical Co Ltd, H1 2018
  • Burns - Pipeline by Lakewood-Amedex Inc, H1 2018
  • Burns - Pipeline by Madam Therapeutics BV, H1 2018
  • Burns - Pipeline by MallInckrodt Plc, H1 2018
  • Burns - Pipeline by MediWound Ltd, H1 2018
  • Burns - Pipeline by NanoBio Corp, H1 2018
  • Burns - Pipeline by Phagelux Inc, H1 2018
  • Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2018
  • Burns - Pipeline by Therapure Biopharma Inc, H1 2018
  • Burns - Pipeline by USV Pvt Ltd, H1 2018
  • Burns - Dormant Projects, H1 2018
  • Burns - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Burns - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Burns, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top